{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:22:45Z","timestamp":1793773365964,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown impressive effects in reducing major vascular events in several randomized controlled trials (RCTs). The purpose of this study was to perform a meta-analysis to evaluate the effect of SGLT2 inhibitors on the risk of stroke and its subtypes. All data from prospective RCTs up to 20 October 2020 involving SGLT2 inhibitors that reported stroke events as the primary endpoint or safety in subjects with type 2 diabetes were subjected to meta-analysis. Five eligible RCTs (EMPA-REG, CANVAS, DECLARE-TIMI 58, CREDENCE and VERTIS CV) involving 46,969 participants were included. Pooled analysis of the RCTs showed no significant effect of SGLT2 inhibitors on total stroke [risk ratio (RR)\u2009=\u20090.95; 95% confidence interval (CI) 0.79\u20131.13, P\u2009=\u20090.585]. Subgroup analysis indicated that SGLT2 inhibitors had no significant effect against fatal stroke, non-fatal stroke, ischemic stroke or transient ischemic attack. When only hemorrhagic stroke was included, SGLT2 inhibitors were associated with a significant 50% reduction compared with placebo (RR\u2009=\u20090.49, 95% CI 0.30\u20130.82, P\u2009=\u20090.007). This meta-analysis shows that SGLT2 inhibitors have a neutral effect on the risk of stroke and its subtypes but a potential protective effect against hemorrhagic stroke.<\/jats:p>","DOI":"10.1038\/s41598-021-94945-4","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T06:02:43Z","timestamp":1627452163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Wen-Hsuan","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ming","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsiang","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Jung","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mou","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"94945_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/pl00002934","volume":"44","author":"NJ Morrish","year":"2001","unstructured":"Morrish, N. J., Wang, S. L., Stevens, L. K., Fuller, J. H. & Keen, H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44, 14\u201321. https:\/\/doi.org\/10.1007\/pl00002934 (2001).","journal-title":"Diabetologia"},{"key":"94945_CR2","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00125-006-0378-1","volume":"49","author":"G Hu","year":"2006","unstructured":"Hu, G., Jousilahti, P., Sarti, C., Antikainen, R. & Tuomilehto, J. The effect of diabetes and stroke at baseline and during follow-up on stroke mortality. Diabetologia 49, 2309\u20132316. https:\/\/doi.org\/10.1007\/s00125-006-0378-1 (2006).","journal-title":"Diabetologia"},{"key":"94945_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao, E. C. & Henry, R. R. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 9, 551\u2013559. https:\/\/doi.org\/10.1038\/nrd3180 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"94945_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","volume":"8","author":"OR Ghosh-Swaby","year":"2020","unstructured":"Ghosh-Swaby, O. R. et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: An updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 8, 418\u2013435. https:\/\/doi.org\/10.1016\/S2213-8587(20)30038-3 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"94945_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720 (2015).","journal-title":"N. Engl. J. Med."},{"key":"94945_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925 (2017).","journal-title":"N. Engl. J. Med."},{"key":"94945_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389 (2019).","journal-title":"N. Engl. J. Med."},{"key":"94945_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744 (2019).","journal-title":"N. Engl. J. Med."},{"key":"94945_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1159\/000210432","volume":"27","author":"P Amarenco","year":"2009","unstructured":"Amarenco, P. et al. Classification of stroke subtypes. Cerebrovasc. Dis. 27, 493\u2013501. https:\/\/doi.org\/10.1159\/000210432 (2009).","journal-title":"Cerebrovasc. Dis."},{"key":"94945_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1561","author":"K Sato","year":"2019","unstructured":"Sato, K., Mano, T., Iwata, A. & Toda, T. Subtype-dependent reporting of stroke with SGLT2 inhibitors: Implications from a Japanese Pharmacovigilance Study. J. Clin. Pharmacol. https:\/\/doi.org\/10.1002\/jcph.1561 (2019).","journal-title":"J. Clin. Pharmacol."},{"key":"94945_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1161\/STROKEAHA.118.023009","volume":"50","author":"Z Zhou","year":"2019","unstructured":"Zhou, Z. et al. Canagliflozin and stroke in type 2 diabetes mellitus. Stroke 50, 396\u2013404. https:\/\/doi.org\/10.1161\/STROKEAHA.118.023009 (2019).","journal-title":"Stroke"},{"key":"94945_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967 (2020).","journal-title":"N. Engl. J. Med."},{"key":"94945_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 393, 31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"94945_CR14","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/dom.13295","volume":"20","author":"M Guo","year":"2018","unstructured":"Guo, M. et al. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes. Metab. 20, 1977\u20131982. https:\/\/doi.org\/10.1111\/dom.13295 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"94945_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/ene.13905","volume":"26","author":"F Barkas","year":"2019","unstructured":"Barkas, F., Elisaf, M. & Milionis, H. Protection against stroke with glucagon-like peptide 1 receptor agonists: A systematic review and meta-analysis. Eur. J. Neurol. 26, 559\u2013565. https:\/\/doi.org\/10.1111\/ene.13905 (2019).","journal-title":"Eur. J. Neurol."},{"key":"94945_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","volume":"48","author":"M Lee","year":"2017","unstructured":"Lee, M., Saver, J. L., Liao, H. W., Lin, C. H. & Ovbiagele, B. Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke 48, 388\u2013393. https:\/\/doi.org\/10.1161\/STROKEAHA.116.013977 (2017).","journal-title":"Stroke"},{"key":"94945_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabet.2016.10.006","volume":"43","author":"F Barkas","year":"2017","unstructured":"Barkas, F., Elisaf, M., Tsimihodimos, V. & Milionis, H. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and metaanalysis. Diabetes Metab. 43, 1\u20138. https:\/\/doi.org\/10.1016\/j.diabet.2016.10.006 (2017).","journal-title":"Diabetes Metab."},{"key":"94945_CR18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1253\/circj.CJ-17-0040","volume":"81","author":"G Kimura","year":"2017","unstructured":"Kimura, G. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and stroke. Circ. J. 81, 898. https:\/\/doi.org\/10.1253\/circj.CJ-17-0040 (2017).","journal-title":"Circ. J."},{"key":"94945_CR19","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","volume":"52","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease. Stroke 52, 1545\u20131556. https:\/\/doi.org\/10.1161\/STROKEAHA.120.031623 (2021).","journal-title":"Stroke"},{"key":"94945_CR20","doi-asserted-by":"publisher","first-page":"k119","DOI":"10.1136\/bmj.k119","volume":"360","author":"E Patorno","year":"2018","unstructured":"Patorno, E. et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: Population based cohort study. BMJ 360, k119. https:\/\/doi.org\/10.1136\/bmj.k119 (2018).","journal-title":"BMJ"},{"key":"94945_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrn2294","volume":"9","author":"DR Tomlinson","year":"2008","unstructured":"Tomlinson, D. R. & Gardiner, N. J. Glucose neurotoxicity. Nat. Rev. Neurosci. 9, 36\u201345. https:\/\/doi.org\/10.1038\/nrn2294 (2008).","journal-title":"Nat. Rev. Neurosci."},{"key":"94945_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/jcbfm.1992.64","volume":"12","author":"N Araki","year":"1992","unstructured":"Araki, N. et al. The effect of hyperglycemia on intracellular calcium in stroke. J. Cereb. Blood Flow Metab. 12, 469\u2013476. https:\/\/doi.org\/10.1038\/jcbfm.1992.64 (1992).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"94945_CR23","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray, K. K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 373, 1765\u20131772. https:\/\/doi.org\/10.1016\/S0140-6736(09)60697-8 (2009).","journal-title":"Lancet"},{"key":"94945_CR24","doi-asserted-by":"publisher","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze, M. et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetesinduced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE 9, e112394. https:\/\/doi.org\/10.1371\/journal.pone.0112394 (2014).","journal-title":"PLoS ONE"},{"key":"94945_CR25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","volume":"60","author":"JH Han","year":"2017","unstructured":"Han, J. H. et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet. Diabetologia 60, 364\u2013376. https:\/\/doi.org\/10.1007\/s00125-016-4158-2 (2017).","journal-title":"Diabetologia"},{"key":"94945_CR26","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1161\/STROKEAHA.118.020586","volume":"49","author":"P Bazzigaluppi","year":"2018","unstructured":"Bazzigaluppi, P. et al. Imaging the effects of \u03b2-hydroxybutyrate on peri-infarct neurovascular function and metabolism. Stroke 49, 2173\u20132181. https:\/\/doi.org\/10.1161\/STROKEAHA.118.020586 (2018).","journal-title":"Stroke"},{"key":"94945_CR27","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini, E., Mark, M. & Mayoux, E. CV protection in the EMPAREG OUTCOME trial: A \u201cthrifty substrate\u201d hypothesis. Diabetes Care 39, 1108\u20131114. https:\/\/doi.org\/10.2337\/dc16-0330 (2016).","journal-title":"Diabetes Care"},{"key":"94945_CR28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"AT Zelniker","year":"2020","unstructured":"Zelniker, A. T. et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 trial. Circulation 141, 1227\u20131234. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044183 (2020).","journal-title":"Circulation"},{"key":"94945_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/00004872-200304000-00013","volume":"21","author":"CM Lawes","year":"2003","unstructured":"Lawes, C. M. et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J. Hypertens. 21, 707\u2013716. https:\/\/doi.org\/10.1097\/00004872-200304000-00013 (2003).","journal-title":"J. Hypertens."},{"key":"94945_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","volume":"387","author":"X Xie","year":"2016","unstructured":"Xie, X. et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. Lancet 387, 435\u2013443. https:\/\/doi.org\/10.1016\/S0140-6736(15)00805-3 (2016).","journal-title":"Lancet"},{"key":"94945_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker, W. L. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J. Am. Soc. Hypertens. 8, 262\u2013275. https:\/\/doi.org\/10.1016\/j.jash.2014.01.007 (2014).","journal-title":"J. Am. Soc. Hypertens."},{"key":"94945_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","volume":"12","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi, S. E. et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab. Vasc. Dis. Res. 12, 90\u2013100. https:\/\/doi.org\/10.1177\/1479164114559852 (2015).","journal-title":"Diab. Vasc. Dis. Res."},{"key":"94945_CR33","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano, M. & Goto, S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139, 1985\u20131987. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038881 (2019).","journal-title":"Circulation"},{"key":"94945_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.atherosclerosis.2015.07.014","volume":"242","author":"S Gotoh","year":"2015","unstructured":"Gotoh, S. et al. Hematocrit and the risk of cardiovascular disease in a Japanese community: The Hisayama Study. Atherosclerosis 242, 199\u2013204. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.07.014 (2015).","journal-title":"Atherosclerosis"},{"key":"94945_CR35","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/ndt\/gfx305","volume":"33","author":"R Yotsueda","year":"2018","unstructured":"Yotsueda, R. et al. Hemoglobin concentration and the risk of hemorrhagic and ischemic stroke in patients undergoing hemodialysis: The Q-cohort study. Nephrol. Dial. Transplant. 33, 856\u2013864. https:\/\/doi.org\/10.1093\/ndt\/gfx305 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"94945_CR36","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/STROKEAHA.116.015756","volume":"48","author":"B Zinman","year":"2017","unstructured":"Zinman, B. et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 48, 1218\u20131225. https:\/\/doi.org\/10.1161\/STROKEAHA.116.015756 (2017).","journal-title":"Stroke"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94945-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94945-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94945-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:50:21Z","timestamp":1670050221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94945-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94945"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94945-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15364"}}